Acute Combined Central and Peripheral Demyelination in Children: in Comparison with Isolated Demyelinating Disease.
- Author:
Joung Hee BYUN
1
;
Ji Yeon SONG
;
Juhyun KONG
;
Sang Ook NAM
;
Young Mi KIM
;
Gyu Min YEON
;
Yun Jin LEE
Author Information
1. Department of Pediatrics, Pusan National University Children's Hospital, Pusan National University School of Medicine, Yangsan, Korea. jinnyeye@hanmail.net
- Publication Type:Original Article
- Keywords:
Demyelinating disease;
Child;
Acute disseminated encephalomyelitis;
Transverse myelitis;
Guillain-Barre syndrome;
Optic neuritis;
Miller-Fisher syndrome
- MeSH:
Adrenal Cortex Hormones;
Child*;
Demyelinating Diseases*;
Encephalomyelitis, Acute Disseminated;
Guillain-Barre Syndrome;
Hospitalization;
Humans;
Immunoglobulins;
Intensive Care Units;
Miller Fisher Syndrome;
Myelitis, Transverse;
Nervous System;
Neuroimaging;
Optic Neuritis;
Peripheral Nervous System;
Plasmapheresis;
Retrospective Studies;
Steroids
- From:
Journal of the Korean Child Neurology Society
2017;25(2):106-112
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study aimed to describe the clinical characteristics and outcomes of children with acute combined central and peripheral nervous system demyelination (CCPD); and compare with the children of isolated acute central or peripheral nervous system demyelination. METHODS: A retrospective chart review of 145 children with acute demyelinating disease between 2010 and 2015 was undertaken in children with younger than 18 years old. Among these, 96 fulfilled criteria (clinical features and positive neuroimaging or electromyography/nerve conduction studies) for either acute central (group A, n=60, 62.5%) or peripheral (group B, n=30, 31.3%) nervous system demyelination, or a CCPD (group C, n=6, 6.3%). RESULTS: Significant differences among the groups (A vs B vs C) were evident for occurrence of disease between 2013-2015 (45.0% vs 43.3% vs 83.3%; P=0.024), admission to intensive care unit (8.3% vs 26.7% vs 50.0%; P=0.027), length of hospitalization (median, 9.7 vs 12.3 vs 48.3 days; P<0.001), treatment with steroids (88.3% vs 10.0 vs 100.0%; P=0.003), immunoglobulins (13.3% vs 100.0% vs 100.0%; P=0.002) and plasmapheresis (0.0% vs 3.3% vs 50.0%; P=0.037) and severe disability at discharge (3.3% vs 16.7% vs 33.3%; P=0.012). Children of group C showed good response to simultaneous use of immunoglobulin and high-dose corticosteroids and earlier try of plasmapheresis, however, two patients had moderate degree of neurological disability. CONCLUSION: Systemic studies using neuroimaing and electromyography/nerve conduction studies in all patients with demyelinating disease will be necessary to verify the combined or isolated disease, because CCPD might have the poorer outcome than isolated disease.
